Literature DB >> 28394856

Brief Report: Prevalence of Posttreatment Controller Phenotype Is Rare in HIV-Infected Persons After Stopping Antiretroviral Therapy.

Matthew J Perkins1, William P Bradley, Tahaniyat Lalani, Brian K Agan, Timothy J Whitman, Tomas M Ferguson, Jason F Okulicz, Anuradha Ganesan.   

Abstract

BACKGROUND: Posttreatment control of HIV infection is a rare phenomenon primarily described among those initiating treatment with antiretroviral therapy (ART) during early/acute HIV infection.
METHODS: We examined a large, well-characterized cohort of HIV-infected Department of Defense beneficiaries for the presence of posttreatment controllers (PTCs) whom we defined as individuals with sustained viral suppression for ≥6 months after discontinuation of ART. We defined those who became viremic within 6 months of discontinuing ART as rapid viremics (RVs) and compared demographic and clinical characteristics, CD4 counts, and viral loads prior, during, and after ART discontinuation between the 2 groups.
RESULTS: From a cohort of 6070 patients, we identified 95 who had been treated with ART for 2 years or more who subsequently discontinued ART and had viral load assessments available after discontinuation. Four (4.2%) of these 95 met our definition of PTC. The duration of viral suppression off of ART ranged from 267 to 1058 days with 1 of the 4 restarting ART without having redeveloped a significant viremia. All 4 patients initiated ART during chronic HIV infection. Demographic and clinical characteristics of PTCs were similar to RVs.
CONCLUSIONS: While posttreatment control has predominantly been described among individuals who initiated ART in early/acute HIV infection, we identified 4 PTCs who started ART during chronic infection suggesting that posttreatment control also occurs among such patients. The rarity of PTCs identified in our cohort is consistent with reports from previous studies.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28394856      PMCID: PMC5473334          DOI: 10.1097/QAI.0000000000001393

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  21 in total

Review 1.  Posttreatment controllers: what do they tell us?

Authors:  Christine Rouzioux; Laurent Hocqueloux; Asier Sáez-Cirión
Journal:  Curr Opin HIV AIDS       Date:  2015-01       Impact factor: 4.283

2.  Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption.

Authors:  Meghan K Rothenberger; Brandon F Keele; Stephen W Wietgrefe; Courtney V Fletcher; Gregory J Beilman; Jeffrey G Chipman; Alexander Khoruts; Jacob D Estes; Jodi Anderson; Samuel P Callisto; Thomas E Schmidt; Ann Thorkelson; Cavan Reilly; Katherine Perkey; Thomas G Reimann; Netanya S Utay; Krystelle Nganou Makamdop; Mario Stevenson; Daniel C Douek; Ashley T Haase; Timothy W Schacker
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-23       Impact factor: 11.205

3.  A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control.

Authors:  Lambert Assoumou; Laurence Weiss; Christophe Piketty; Marianne Burgard; Adeline Melard; Pierre-Marie Girard; Christine Rouzioux; Dominique Costagliola
Journal:  AIDS       Date:  2015-09-24       Impact factor: 4.177

4.  Treatment interruption after 2-year antiretroviral treatment initiated during acute/early HIV in infancy.

Authors:  Dalton Wamalwa; Sarah Benki-Nugent; Agnes Langat; Kenneth Tapia; Evelyn Ngugi; Helen Moraa; Elizabeth Maleche-Obimbo; Vincent Otieno; Irene Inwani; Barbra A Richardson; Bhavna Chohan; Julie Overbaugh; Grace C John-Stewart
Journal:  AIDS       Date:  2016-09-24       Impact factor: 4.177

5.  Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study.

Authors:  Jason F Okulicz; Vincent C Marconi; Michael L Landrum; Scott Wegner; Amy Weintrob; Anuradha Ganesan; Braden Hale; Nancy Crum-Cianflone; Judith Delmar; Vincent Barthel; Gerald Quinnan; Brian K Agan; Matthew J Dolan
Journal:  J Infect Dis       Date:  2009-12-01       Impact factor: 5.226

6.  Epidemiology of Hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years.

Authors:  Helen M Chun; Ann M Fieberg; Katherine Huppler Hullsiek; Alan R Lifson; Nancy F Crum-Cianflone; Amy C Weintrob; Anuradha Ganesan; Robert V Barthel; William P Bradley; Brian K Agan; Michael L Landrum
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

7.  No evidence of posttreatment control after early initiation of antiretroviral therapy.

Authors:  Sara Gianella; Christy M Anderson; Douglas D Richman; Davey M Smith; Susan J Little
Journal:  AIDS       Date:  2015-10-23       Impact factor: 4.177

8.  Control of viral replication after cessation of HAART.

Authors:  Ellen Van Gulck; Leo Heyndrickx; Lotte Bracke; Sandra Coppens; Eric Florence; Anne Buvé; Paul Lewi; Guido Vanham
Journal:  AIDS Res Ther       Date:  2011-02-11       Impact factor: 2.250

9.  Immune and viral correlates of "secondary viral control" after treatment interruption in chronically HIV-1 infected patients.

Authors:  Ellen Van Gulck; Lotte Bracke; Leo Heyndrickx; Sandra Coppens; Derek Atkinson; Céline Merlin; Alexander Pasternak; Eric Florence; Guido Vanham
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

10.  Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection.

Authors:  Genevieve E Martin; Morgane Gossez; James P Williams; Wolfgang Stöhr; Jodi Meyerowitz; Ellen M Leitman; Philip Goulder; Kholoud Porter; Sarah Fidler; John Frater
Journal:  AIDS       Date:  2017-02-20       Impact factor: 4.177

View more
  6 in total

Review 1.  Challenges and Promise of Human Immunodeficiency Virus Remission.

Authors:  Yijia Li; Abbas Mohammadi; Jonathan Z Li
Journal:  J Infect Dis       Date:  2021-02-15       Impact factor: 5.226

2.  A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation.

Authors:  Avy Violari; Mark F Cotton; Louise Kuhn; Diana B Schramm; Maria Paximadis; Shayne Loubser; Sharon Shalekoff; Bianca Da Costa Dias; Kennedy Otwombe; Afaaf Liberty; James McIntyre; Abdel Babiker; Diana Gibb; Caroline T Tiemessen
Journal:  Nat Commun       Date:  2019-01-24       Impact factor: 14.919

Review 3.  Learning From the Exceptions: HIV Remission in Post-treatment Controllers.

Authors:  Behzad Etemad; Elmira Esmaeilzadeh; Jonathan Z Li
Journal:  Front Immunol       Date:  2019-07-24       Impact factor: 7.561

4.  Virological Outcome Measures During Analytical Treatment Interruptions in Chronic HIV-1-Infected Patients.

Authors:  Csaba Fehér; Lorna Leal; Montserrat Plana; Nuria Climent; Alberto Crespo Guardo; Esteban Martínez; Pedro Castro; Vicens Díaz-Brito; Beatriz Mothe; Juan Carlos López Bernaldo De Quirós; Josep María Gatell; Patrick Aloy; Felipe García
Journal:  Open Forum Infect Dis       Date:  2019-11-03       Impact factor: 3.835

Review 5.  Forging a Functional Cure for HIV: Transcription Regulators and Inhibitors.

Authors:  Sonia Mediouni; Shuang Lyu; Susan M Schader; Susana T Valente
Journal:  Viruses       Date:  2022-09-07       Impact factor: 5.818

Review 6.  How elite controllers and posttreatment controllers inform our search for an HIV-1 cure.

Authors:  Jonathan Z Li; Joel N Blankson
Journal:  J Clin Invest       Date:  2021-06-01       Impact factor: 19.456

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.